cbdMD, Inc. (YCBD) Stock Score, Valuation & Financial Research
cbdMD, Inc. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 15/100.
Quick answer for YCBD
cbdMD, Inc. currently has a Wall Street Score of 15/100. The stored market price is $0.47. Its financial score is 12/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What cbdMD, Inc. does
cbdMD, Inc. is engaged in the production and distribution of a diverse array of cannabidiol (CBD) products. The company oversees and markets several consumer-oriented, hemp-derived CBD brands, notably its primary brand cbdMD, alongside Paw CBD and cbdMD Botanicals. Under the cbdMD label, its offerings span various items, including CBD tinctures, edible gummies, topical applications, capsules, bath bombs, bath salts, and solutions designed to aid sleep. Furthermore, its Paw CBD brand caters to pets with veterinarian-formulated products such as tinctures, edible chews, and topical treatments. The company's merchandise reaches customers throughout the United States via its proprietary e-commerce platform, various third-party online retail sites, wholesale partners, and physical brick-and-mortar establishments. cbdMD, Inc. also maintains a research collaboration with the University of Missis
YCBD financial snapshot
- Wall Street Score:
- 15/100
- Current price:
- $0.47
- Market capitalization:
- $4.9M
- Revenue:
- $20.9M
- Net income:
- $-2.9M
- Free cash flow:
- $-1.6M
- Cash:
- $2.1M
- Total debt:
- $2.2M
- EPS:
- -0.31
- Financial score:
- 12/100
- Valuation score:
- 0/100
- Revenue score:
- 29/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-1.6M, showing cash burn in the current stored period.
- The balance sheet shows $2.1M of cash versus $2.2M of total debt, so leverage deserves attention.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research YCBD
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.